ANXA5 and urinary bladder cancer: MDSCs isolated from the peripheral blood of patients with bladder cancer or melanoma were treated for 48 h with PLX51107, leading to a 1.5-fold increase of annexin V+ MDSCs (Figure 4, F and G; P < 0.0001 for melanoma, P < 0.01 for bladder cancer).